<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2183-8453</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Saúde Ocupacional online]]></journal-title>
<abbrev-journal-title><![CDATA[RPSO]]></abbrev-journal-title>
<issn>2183-8453</issn>
<publisher>
<publisher-name><![CDATA[Ajeogene Serviços Médicos Lda]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2183-84532022000100023</article-id>
<article-id pub-id-type="doi">10.31252/rpso.07.05.2022</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[VACINA COVID-19: QUANTO VALEM OS ANTICORPOS?]]></article-title>
<article-title xml:lang="en"><![CDATA[COVID-19 VACCINE: HOW MUCH ARE ANTIBODIES WORTH?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Peixoto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vilaça]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade de Coimbra Centro Hospitalar Tâmega e Sousa Formação Específica de Medicina do Trabalho]]></institution>
<addr-line><![CDATA[Guimarães ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Enfermeiro Especialista em Reabilitação com Competência acrescida diferenciada em Enfermagem do Trabalho e em Enfermagem no Desporto  ]]></institution>
<addr-line><![CDATA[Guimarães ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Diretora do Serviço de Medicina do Trabalho do Hospital Senhora da Oliveira  ]]></institution>
<addr-line><![CDATA[Guimarães ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>13</volume>
<fpage>23</fpage>
<lpage>34</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2183-84532022000100023&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2183-84532022000100023&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2183-84532022000100023&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução Desde o aparecimento dos primeiros casos de COVID-19 que a pandemia apresentou um rápido crescimento com impacto à escala global. A capacidade de gerar imunidade é um fator chave para o seu controlo, tendo sido por isso sido alvo de investigação científica aprofundada até ao momento. Contudo, e apesar da administração generalizada de vacinas, mantêm-se várias dúvidas quanto à imunogenicidade das mesmas. A literatura sugere que tanto idade, sexo, bem como o estado serológico prévio, influenciam a diferença na resposta imunitária humoral. A seropositividade, idade jovem e o sexo feminino parecem ter uma influência positiva no nível de anticorpos, na maior parte dos estudos publicados até ao momento.  Objetivo O objetivo deste estudo é avaliar a resposta humoral à vacina Pfizer-BionNTech, em profissionais de saúde seronegativos de um hospital periférico, por um período de seis meses, bem como a influência da seropositividade prévia, da idade e sexo.  Métodos Tanto os profissionais com serologias positivas como negativas foram vacinados com duas doses. Procedeu-se à análise da influência das variáveis idade, sexo e estado serológico prévio nos níveis de anticorpos ao longo de seis meses. Foi feito o doseamento dos anticorpos através do imunoensaio de quimioluminescência IgG SARS-CoV-2 da Abbott (SARS-CoV-2 IgG II Quant®) em quatro tempos: previamente à primeira inoculação de vacina, assim como ao primeiro, terceiro e sexto mês após a segunda inoculação. O estudo incluiu uma amostra inicial de 1387 profissionais de saúde, mas apenas 391 cumpriram rigorosamente os quatro tempos supracitados. Da amostra final de 391 colaboradores, 341 apresentavam serologia negativa previamente à vacinação e não tinham história de RT-PCR positivo para COVID-19. Os restantes 50 apresentavam serologia positiva (&gt;6.8 AU/mL).  Resultados Observa-se que existe uma resposta mais robusta em indivíduos previamente seropositivos, tendo apresentado um valor quantitativo mais elevado de IgG, mas com um comportamento semelhante aos seronegativos no que respeita à sustentabilidade. Os anticorpos atingiram o pico no primeiro mês, especialmente em indivíduos mais jovens, apresentando declínio progressivo no semestre pós-vacinação para ambos os grupos. Numa população em que o sexo feminino é predominante, foi este que teve uma resposta quantitativa mais robusta para IgG. Por fim, verificamos uma diminuição marcada no número de infeções sintomáticas por COVID-19 após a imunização, que é transversal a toda a literatura atual.  Conclusão Em suma, concluímos que indivíduos previamente infetados vacinados com duas doses têm o mesmo comportamento serológico, no que se refere à imunidade humoral, comparativamente aos não infetados vacinados com duas doses. Este resultado veio reforçar que o doseamento da imunidade humoral não pode ser utilizado como ferramenta de decisão clínica para a seleção e priorização de indivíduos a vacinar.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction Since the appearance of the first cases of COVID-19, the pandemic has shown rapid growth with an impact on a global scale. The ability to generate immunity is a key factor for its control, which is why it has been a topic of exhaustive scientific investigation so far. However, despite the widespread administration of vaccines, several doubts remain as to their immunogenicity. The literature suggests that age, gender, and previous serological status influence the difference in humoral immune response. Seropositivity, young age and female gender seem to have a positive influence on antibody levels in most studies published so far.  Objectives The aim of this study is to evaluate the humoral response to the Pfizer-BionNTech vaccine in healthcare professionals at a hospital.  Methods Professionals with both positive and negative serology were inoculated with two doses. The influence of age, gender and previous serological status on antibody levels was analyzed over a period of six months. Antibodies were assayed using Abbott's SARS-CoV-2 IgG chemiluminescence immunoassay (SARS-CoV-2 IgG II Quant®) in four stages: prior to the first vaccine inoculation, as well as on the first, third and sixth month after the second inoculation. The study included an initial sample of 1387 health professionals, but only 391 strictly complied with the 4 stages mentioned above. Of the final sample of 391 collaborators, 341 had negative serology prior to vaccination, and had no history of positive RT-PCR for COVID-19. The remaining 50 had positive serology (&gt;6.8 AU/mL).  Results It is observed that there is a more robust response in previously seropositive individuals, having presented a higher quantitative value of IgG, but with a similar behaviour to seronegatives regarding sustainability. Antibodies peaked in the first month, especially in younger subjects, showing a progressive decline in the post-vaccination semester for both groups. In a population where the female sex is predominant, it was this one that had a more robust quantitative response to IgG. Finally, we found a marked decrease in the number of symptomatic infections by COVID-19 after immunization, which is transversal to all the current literature.  Conclusion In summary, we conclude that previously infected individuals vaccinated with two doses have the same serological behavior regarding humoral immunity compared to uninfected individuals vaccinated with two doses. This result reinforces that the humoral immunity assay cannot be utilized as a clinical tool for the selection and prioritization of whom to vaccinate.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="pt"><![CDATA[Vacina BNT162]]></kwd>
<kwd lng="pt"><![CDATA[Imunidade]]></kwd>
<kwd lng="pt"><![CDATA[Saúde Ocupacional]]></kwd>
<kwd lng="pt"><![CDATA[COVID19.]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[BNT162 Vaccine]]></kwd>
<kwd lng="en"><![CDATA[Immunity]]></kwd>
<kwd lng="en"><![CDATA[Occupational Health]]></kwd>
<kwd lng="en"><![CDATA[COVID 19.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>WHO</collab>
<source><![CDATA[Coronavirus disease (COVID-19)]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamouche]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human resource management and the COVID-19 crisis: implications, challenges, opportunities, and future organizational directions]]></article-title>
<source><![CDATA[Journal of Management &amp; Organization]]></source>
<year>2021</year>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caligiuri]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cieri]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Minbaeva]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Verbeke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmermann]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International HRM insights for navigating the COVID-19 pandemic: Implications for future research and practice]]></article-title>
<source><![CDATA[Journal of International Business Studies]]></source>
<year>2020</year>
<volume>51</volume>
<page-range>697-713</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ralph]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lew]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Roux]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019-nCoV (Wuhan virus), a novel Coronavirus: Human-to-human transmission, travel-related cases, and vaccine readiness]]></article-title>
<source><![CDATA[Journal of Infection in Developing Countries]]></source>
<year>2020</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-17</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Papenburg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Desjardins]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kanjilal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Quach]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Libman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review]]></article-title>
<source><![CDATA[Annals of Internal Medicine]]></source>
<year>2020</year>
<volume>172</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>726-34</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>DGS</collab>
<article-title xml:lang=""><![CDATA[Saúde e Trabalho. Medidas de prevenção da COVID-19 nas empresas]]></article-title>
<source><![CDATA[Direção-Geral da Saúde, editor]]></source>
<year>2020</year>
<page-range>1-18</page-range><publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>OSHA</collab>
<source><![CDATA[Protecting Workers: Guidance on Mitigating and Preventing the Spread of COVID-19 in the Workplace]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>WHO</collab>
<source><![CDATA[Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection. World Health Organization]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Geneve ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deeks]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dinnes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Takwoingi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Davenport]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Spijker]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor-Phillips]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody tests for identification of current and past infection with SARS-CoV-2]]></article-title>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2020</year>
<numero>6</numero>
<issue>6</issue>
<page-range>CD013652</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ren]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)]]></article-title>
<source><![CDATA[Clinical Infectious Diseases]]></source>
<year>2020</year>
<volume>71</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>778-85</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perspectives on therapeutic neutralizing antibodies against the novel coronavirus sars-cov-2]]></article-title>
<source><![CDATA[International Journal of Biological Sciences]]></source>
<year>2020</year>
<volume>16</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1718-23</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Leite]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morais]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bento]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Em época de Pandemia: Covid-19 como Doença Profissional- a experiência de um Instituto Português de Oncologia]]></article-title>
<source><![CDATA[Revista Portuguesa de Saúde Ocupacional online]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<collab>iMM</collab>
<source><![CDATA[Painel Serológico Nacional COVID-19 (PSN)]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China]]></article-title>
<source><![CDATA[Nature Medicine]]></source>
<year>2020</year>
<volume>26</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1193-5</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Lei]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seropositive Prevalence of Antibodies Against SARS-CoV-2 in Wuhan, China]]></article-title>
<source><![CDATA[JAMA Network Open]]></source>
<year>2020</year>
<volume>3</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>e2025717</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Theel]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Slev]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wheeler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Couturier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kadkhoda]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of antibody testing for sars-cov-2: Is there one?]]></article-title>
<source><![CDATA[Journal of Clinical Microbiology]]></source>
<year>2020</year>
<volume>58</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>e00797-20</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sethuraman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Jeremiah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ryo]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interpreting Diagnostic Tests for SARS-CoV-2]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2020</year>
<volume>323</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2249-51</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Profile of specific antibodies to SARS-CoV-2: The first report]]></article-title>
<source><![CDATA[Journal of Infection]]></source>
<year>2020</year>
<volume>81</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>147-78</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mateus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kato]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Hastie]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Faliti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection]]></article-title>
<source><![CDATA[Science]]></source>
<year>2021</year>
<volume>371</volume>
<numero>6529</numero>
<issue>6529</issue>
<page-range>eabf4063</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kalaidina]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Goss]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rauseo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2021</year>
<volume>595</volume>
<page-range>421-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
